- ISIN
- US0053291078
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 9, 2021
Highlights
- Market Cap
- $131.16M
- Enterprise Value
- $67.88M
- EPS (TTM)
- -$1.35
- Total Revenue (TTM)
- $7.80M
- Gross Profit (TTM)
- $6.29M
- EBITDA (TTM)
- -$50.04M
- Year Range
- $1.30 - $4.75
- Target Price
- $5.00
- ROA (TTM)
- -65.26%
- ROE (TTM)
- -144.50%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ADAG Performance Chart
Adagene Inc. (ADAG) is up 83.1% since the beginning of the year. At $3 per share, ADAG is trading 27.2% below its 52-week high of $5. Investors who bought $1,000 worth of ADAG shares 5 years ago would now be looking at an investment worth $251.
Loading charts...
Returns By Period
Adagene Inc. (ADAG) has returned 83.07% so far this year and 67.15% over the past 12 months.
Adagene Inc.
- 1D
- 2.06%
- 1M
- -5.46%
- YTD
- 83.07%
- 6M
- 67.96%
- 1Y
- 67.15%
- 3Y*
- 37.53%
- 5Y*
- -24.15%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
ADAG Monthly Returns History
Based on dividend-adjusted daily data since Feb 9, 2021, ADAG's average daily return is -0.01%, while the average monthly return is -1.26%.
Historically, 42% of months were positive and 58% were negative. The best month was Jan 2024 with a return of +89.5%, while the worst month was Mar 2022 at -35.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ADAG closed higher 43% of trading days. The best single day was Jun 26, 2023 with a return of +30.4%, while the worst single day was Jan 19, 2024 at -21.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 45.50% | 7.64% | 32.43% | -6.12% | 7.88% | -12.85% | 83.07% | ||||||
| 2025 | -4.52% | 5.79% | -24.38% | -0.00% | 27.63% | 0.52% | 2.05% | 7.04% | -6.57% | -10.55% | 12.92% | -5.97% | -5.03% |
| 2024 | 89.50% | -12.57% | -12.50% | -19.29% | 23.89% | 9.32% | -16.40% | 9.42% | -20.71% | 28.38% | -18.07% | -14.78% | 3.03% |
| 2023 | 44.91% | -13.35% | -12.84% | -9.66% | 0.76% | 12.12% | -8.11% | 0.00% | 12.50% | -11.44% | 29.15% | 10.37% | 45.77% |
| 2022 | -10.27% | -24.86% | -35.66% | 4.29% | -23.29% | -26.22% | -18.19% | -13.61% | -12.33% | -29.69% | 20.00% | 22.69% | -83.58% |
| 2021 | -18.31% | -26.73% | -18.66% | -2.88% | -4.37% | 14.09% | 4.46% | -11.11% | -21.75% | -26.87% | -1.84% | -73.10% |
Benchmark Metrics
Adagene Inc. has an annualized alpha of -7.00%, beta of 0.36, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 10, 2021.
- This stock participated in 159.32% of S&P 500 Index downside but only -21.86% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.36 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.00%
- Beta
- 0.36
- R²
- 0.00
- Upside Capture
- -21.86%
- Downside Capture
- 159.32%
Return for Risk
Risk / Return Rank
ADAG ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Adagene Inc. (ADAG) and compare them to S&P 500 Index.
| ADAG | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.56 | ||
| Sortino ratioReturn per unit of downside risk | -1.40 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.41 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 1.54 | 2.93 | -1.39 |
| Martin ratioReturn relative to average drawdown | 3.66 | 13.52 | -9.86 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Adagene Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Adagene Inc. was 97.00%, occurring on Oct 31, 2022. The portfolio has not yet recovered.
The current Adagene Inc. drawdown is 88.46%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -97.00%Oct 2022 | 1y 8mo | — | 5y 3moFeb 2021 - now |
Drawdown Indicators
| ADAG | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.00% | -56.78% | -40.22% |
Max Drawdown (1Y)Largest decline over 1 year | -43.80% | -9.10% | -34.70% |
Max Drawdown (3Y)Largest decline over 3 years | -66.51% | -18.90% | -47.61% |
Max Drawdown (5Y)Largest decline over 5 years | -95.65% | -25.43% | -70.22% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -88.46% | -0.74% | -87.72% |
Average DrawdownAverage peak-to-trough decline | -85.03% | -10.72% | -74.31% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.59% | 1.97% | +16.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Adagene Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Adagene Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ADAG relative to other companies in the Biotechnology industry. Currently, ADAG has a P/S ratio of 16.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ADAG in comparison with other companies in the Biotechnology industry. Currently, ADAG has a P/B value of 3.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ADAG
Add Adagene Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ADAG